Who founded Stipple Bio?

Stipple Bio was founded by Aaron Ring, Aashish Manglik in 2021.

Who are Stipple Bio's investors?

Stipple Bio's investors include RA Capital, Andreessen Horowitz, GV (Google Ventures), Magnetic Ventures, OMX Ventures, Axial VC, LoLa Capital Partners, Nextech Invest.

How much funding has Stipple Bio raised?

Stipple Bio has disclosed $86.6M raised across 3 rounds.

Where is Stipple Bio headquartered?

Stipple Bio is headquartered in Cambridge, US.

Stipple Bio

Cambridge, US · Founded 2021 · Delaware corporation · 17 employees on LinkedIn · 8 known investors

Find your way into Stipple Bio

Paths you didn't know you had: your email and LinkedIn already hold routes to the Stipple Bio team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Stipple Bio develops targeted oncology therapies that act on tumor-specific cell surface epitopes to expand druggable targets and improve therapeutic index for cancer patients. The company was founded by cancer biology researchers and focuses on discovering and developing precision cancer medicines.

Biotech Healthtech

Founders & leadership

Stipple Bio was founded in 2021 by Aaron Ring and Aashish Manglik.

Aaron RingCo-Founder

Aashish Manglik Co-founderAashish Manglik is a physician-scientist with expertise in G protein-coupled receptor biology and biochemistry. He is co-founder of Stipple Bio, which develops targeted oncology therapies for cancer patients.

Jeff Landau Chief Executive OfficerCEO of Stipple Bio, a company developing targeted oncology therapies for cancer patients. Landau has experience in biotech company building and serves on boards.

Roland Gendron Chief Business OfficerChief Business Officer at Stipple Bio, a precision oncology company developing targeted therapies for cancer. Gendron brings 25+ years of pharmaceutical industry experience spanning corporate development, commercial strategy, alliance management, and R&D across multiple leadership roles.

Michelle Zhang Chief Scientific OfficerShe has extensive experience in drug discovery and development across multiple therapeutic modalities including small molecules, antibodies, and radiopharmaceuticals, with demonstrated expertise in translational research, clinical development strategy, and team leadership in R&D organizations.

Board

Vineeta Agarwala Board directorGeneral Partner at Andreessen Horowitz

Antoine YverBoard director

Owen HughesBoard director

Greg VerdineBoard director

Investors · 8

RA Capital✓ confirmed by Stipple BioBostonvia Derek DiRocco · board

How we know: the company's own site · RA Capital's portfolio page · board seat on SEC Form D · press coverage · funding news · Not right? Tell us

Andreessen Horowitzlisted by Andreessen HorowitzMenlo Park · $500K – $50Mvia Vineeta Agarwala · board

How we know: a16z's portfolio · a partner's Signal profile · board seat on SEC Form D · Not right? Tell us

GV (Google Ventures)listed by GV (Google Ventures)Mountain View · $250K – $50M

How we know: GV (Google Ventures)'s portfolio page · press coverage · funding news · open dataset · 5k.vc investor directory · Not right? Tell us

Magnetic Ventureslisted by Magnetic VenturesBoston · $1M – $6M

How we know: Magnetic Ventures's portfolio page · Not right? Tell us

OMX Ventureslisted by OMX VenturesLincolnshire

How we know: the VCSheet dataset · Not right? Tell us

Axial VCreportedSan Francisco · $100K – $5M

How we know: the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us

LoLa Capital PartnersreportedBoston

How we know: press coverage · Not right? Tell us

Nextech InvestreportedZurich · $648K – $3.2M

How we know: a partner's Signal profile · press coverage · funding news · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$86.6M disclosed across 3 rounds · 2022–2026

▶$65.1MraisedApr 2026 · 15 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Vineeta AgarwalaDirector
Greg VerdineDirector
Thilo SchroederDirector
Owen HughesDirector
Aaron RingDirector
Derek DiRoccoDirector
Jeffrey LandauExecutive Officer, Director

Offering amount: $100.2M
Amount sold: $65.1M
First sale: Mar 2026
Incorporated: Corporation, Delaware, 2021
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$9.5MraisedDec 2024 · 1 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Vineeta AgarwalaDirector
Antoine YverDirector
Owen HughesDirector
Aaron RingExecutive Officer, Director
Greg VerdineDirector

Offering amount: $15M
Amount sold: $9.5M
First sale: Dec 2024
Incorporated: Corporation, Delaware, 2021
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$12MraisedJun 2022 · 7 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Aaron RingExecutive Officer, Director
Vineeta AgarwalaDirector

Offering amount: $12M
Amount sold: $12M
First sale: May 2022
Incorporated: Corporation, Delaware, 2021
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 4

Krystal BiotechKrystal Biotech discovers, develops, and commercializes genetic medicines, including gene therapy programs for rare diseases such as dermatological conditions. The company operates across the US, Europe, and Japan.

Treeline BiosciencesTreeline develops therapeutics focused on oncology, leveraging insights from clinical practice and laboratory research. The company serves cancer patients through drug discovery and development.

Talus BioTalus develops a proprietary platform that measures and modulates the regulome—the body's gene expression control system—in native cellular contexts. The company designs AI-driven compounds and uses functional proteomics to enable drug discovery for transcription factors and regulatory proteins implicated in oncology, rare disease, and immune dysfunction.

Fortis Life SciencesFortis Life Sciences develops and manufactures Bethyl-branded ELISA kits and related reagents, buffers, and antibodies for detecting target proteins in research and diagnostic applications. The kits cover human and veterinary targets and are made in the USA using the company's own antibodies.

Companies working in the same space as Stipple Bio.

In the news

Stipple Bio Emerges From Stealth with Oversubscribed $100 Million Series A Financing to Advance STP-100 into Early Clinical Studies and Advance a Precision Oncology Pipeline that Leverages its Pointillist Platformglobenewswire.com · Apr 2026

Stipple Bio Raises $100M in Series A Financingfinsmes.com · Apr 2026

Frequently asked questions

What does Stipple Bio do?: Stipple Bio develops targeted oncology therapies that act on tumor-specific cell surface epitopes to expand druggable targets and improve therapeutic index for cancer patients. The company was founded by cancer biology researchers and focuses on discovering and developing precision cancer medicines.
Who founded Stipple Bio?: Stipple Bio was founded by Aaron Ring, Aashish Manglik in 2021.
Who are Stipple Bio's investors?: Stipple Bio's investors include RA Capital, Andreessen Horowitz, GV (Google Ventures), Magnetic Ventures, OMX Ventures, Axial VC, LoLa Capital Partners, Nextech Invest.
How much funding has Stipple Bio raised?: Stipple Bio has disclosed $86.6M raised across 3 rounds.
Where is Stipple Bio headquartered?: Stipple Bio is headquartered in Cambridge, US.